Terminated PHASE2/PHASE3 INTERVENTIONAL NCT00221637

Efficacy of Valproate in Peripheral Neuropathic Pain

Efficacy of a Therapeutic Strategy in Peripheral Neuropathic Pain: Intravenous Sodium Valproate Followed by Oral Route Treatment Versus Placebo (Clinical and Neurophysiologic Evaluation)

Sponsor: Sanofi-Synthelabo

Conditions Neuralgia Neuropathic Peripheral Pain

Interventions Sodium Valproate

Updated 5 times since 2017 Last updated: Jun 12, 2007 Started: Mar 31, 2002 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow recruitment and treatments beyond expiry date

Other terminated trials from Sanofi-Synthelabo

More terminations from Sanofi-Synthelabo

Other Neuralgia trials with similar outcome

Browse all Neuralgia trials

This PHASE2/PHASE3 trial investigates Neuralgia and Neuropathic Peripheral Pain and is currently terminated or withdrawn. Sanofi-Synthelabo leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi-Synthelabo
University Hospital, Bordeaux

Data source: University Hospital, Bordeaux

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bordeaux, France